Recursion
41 S. Rio Grande Street
Salt Lake City
Utah
84101
United States
Tel: 801-587-1629
Fax: 801-581-7895
Website: https://www.recursion.com/
Email: info@recursion.com
About Recursion
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to radically improve the lives of patients and industrialize drug discovery. Our team is working to solve some of the hardest, most meaningful problems facing human health today.
Recursion is proudly headquartered in Salt Lake City, Utah with offices in Toronto, Montreal and Milpitas, California. We're working to solve some of the most meaningful problems facing human health today. Come do the most impactful work of your career at a company that prioritizes belonging, collaboration and career development.
Recursion 101: A Biotechnology Company Industrializing Drug Discovery
74 articles with Recursion
-
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results
2/27/2023
Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2022.
-
Recursion to Participate in Upcoming Investor Conference - February 1, 2023
2/1/2023
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference.
-
Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day
1/26/2023
Recursion announced the public release of MolRec™ - one of its many interactive internal tools to explore the company's proprietary maps of biology and chemistry.
-
Recursion to Participate in Upcoming January 2023 Investor Conferences
12/20/2022
Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced its participation in the following investor conferences.
-
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results
11/8/2022
Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business updates and financial results for its third quarter ending September 30, 2022.
-
Recursion to Participate in Upcoming November 2022 Investor Conferences
11/2/2022
Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced its participation in the following November 2022 investor conferences.
-
Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB
10/25/2022
Recursion announced that it has entered into a stock purchase agreement for the sale of an aggregate of approximately 15.3 million shares of its Class A common stock in a private placement, led by Kinnevik AB, with participation by Baillie Gifford, Mubadala Investment Company, Laurion Capital Management, Invus, and Platinum Asset Management.
-
Recursion to Participate in Upcoming September 2022 Investor Conferences
9/1/2022
Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced its participation in the following investor conferences:
-
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum
8/18/2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional Shareholder Services (ISS), which is the first time Recursion has been ranked by ISS.
-
Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results
8/9/2022
Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, reported business updates and financial results for its second quarter ending June 30, 2022.
-
Recursion to Participate in Upcoming Investor Conference
8/2/2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference.
-
Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
7/21/2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the European Commission has granted Recursion Orphan Drug Designation for REC-4881 for the potential treatment of familial adenomatous polyposis (FAP).
-
Recursion to Participate in Upcoming Investor Conferences - June 02, 2022
6/2/2022
Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced its participation in the following upcoming investor conferences:
-
Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results
5/10/2022
Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business updates and financial results for its first quarter ending March 31, 2022.
-
Recursion to Participate in Upcoming Investor Conference - May 02, 2022
5/2/2022
Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced its participation in the following upcoming investor conference.
-
Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
4/11/2022
Recursion today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for REC-4881 for the potential treatment of familial adenomatous polyposis (FAP).
-
Recursion to Participate in Upcoming Investor Conferences in April 2022
3/31/2022
Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced its participation in the following upcoming investor conferences:
-
Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital
3/30/2022
Altitude Lab announced its first cohort of startups raised $54M in seed funding while incubating at Altitude Lab.
-
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
3/23/2022
Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021.
-
It was a busy week for clinical trial announcements. Here's a look.